From new findings in acne pathogenesis to new approaches in treatment

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue S5, 2015, Pages 1-7

  Gollnick, H P M ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BENZOYL PEROXIDE; DERMATOLOGICAL AGENT; DRUG COMBINATION; RETINOID;

ACNE VULGARIS; DRUG COMBINATION; HUMAN; KERATINOCYTE; PATHOLOGY; PATHOPHYSIOLOGY; PHOTOCHEMOTHERAPY; TREATMENT OUTCOME;

ACNE VULGARIS; ANTI-BACTERIAL AGENTS; BENZOYL PEROXIDE; DERMATOLOGIC AGENTS; DRUG COMBINATIONS; HUMANS; KERATINOCYTES; PHOTOCHEMOTHERAPY; RETINOIDS; TREATMENT OUTCOME;

EID: 84991247813     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/JDV.13186     Document Type: Review

References (53)

1. Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet 2012; 379: 361–372.
2. Gollnick HP, Finlay AY, Shear N. Can we define acne as a chronic dis-ease? If so, how and when? Am J Clin Dermatol 2008; 9: 279–284.
3. Rademaker M, Garioch JJ, Simpson NB. Acne in schoolchildren: no longer a concern for dermatologists. BMJ 1989; 298: 1217–1219.
4. Karciauskiene J, Valiukeviciene S, Gollnick H, Stang A. The prevalence and risk factors of adolescent acne among schoolchildren in Lithuania: a cross-sectional study. J Eur Acad Dermatol Venereol 2014; 28: 733–740.
5. Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol 2013; 168: 474–485.
6. Collier CN, Harper JC, Cafardi JA et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol 2008; 58: 56–59.
7. Thiboutot D, Gollnick H, Bettoli V et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009; 60: S1–S50.
8. Zaenglein AL, Thiboutot DM. Expert committee recommendations for acne management. Pediatrics 2006; 118: 1188–1199.
9. Gollnick HP, Zouboulis CC, Akamatsu H, Kurokawa I, Schulte A. Patho-genesis and pathogenesis related treatment of acne. J Dermatol 1991; 18: 489–499.
10. Akamatsu H, Zouboulis CC, Orfanos CE. Control of human sebocyte proliferation in vitro by testosterone and 5-alpha-dihydrotestosterone is dependent on the localization of the sebaceous glands. J Invest Dermatol 1992; 99: 509–511.
11. Schneider MR, Paus R. Sebocytes, multifaceted epithelial cells: lipid production and holocrine secretion. Int J Biochem Cell Biol 2010; 42: 181– 185.
12. Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. Endocr Rev 2000; 21: 363–392.
13. Nast A, Dreno B, Bettoli V et al. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol 2012; 26(Suppl. 1): 1–29.
14. Cunliffe WJ, Holland DB, Clark SM, Stables GI. Comedogenesis: some new aetiological, clinical and therapeutic strategies. Br J Dermatol 2000; 142: 1084–1091.
15. Beylot C, Auffret N, Poli F et al. Propionibacterium acnes: an update on its role in the pathogenesis of acne. J Eur Acad Dermatol Venereol 2014; 28: 271–278.
16. Valins W, Amini S, Berman B. The expression of Toll-like receptors in dermatological diseases and the therapeutic effect of current and newer topical Toll-like receptor modulators. J Clin Aesthet Dermatol 2010; 3: 20–29.
17. Kim J, Ochoa MT, Krutzik SR et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 2002; 169: 1535–1541.
18. Agak GW, Qin M, Nobe J et al. Propionibacterium acnes induces an IL-17 response in acne vulgaris that is regulated by vitamin A and vitamin D. J Invest Dermatol 2014; 134: 366–373.
19. Pawin H, Beylot C, Chivot M et al. Physiopathology of acne vulgaris: recent data, new understanding of the treatments. Eur J Dermatol 2004; 14: 4–12.
20. Jugeau S, Tenaud I, Knol AC et al. Induction of toll-like receptors by Pro-pionibacterium acnes. Br J Dermatol 2005; 153: 1105–1113.
21. Guy R, Green MR, Kealey T. Modeling acne in vitro. J Invest Dermatol 1996; 106: 176–182.
22. Jahns AC, Lundskog B, Ganceviciene R et al. An increased incidence of Propionibacterium acnes biofilms in acne vulgaris: a case-control study. Br J Dermatol 2012; 167: 50–58.
23. Bayston R, Nuradeen B, Ashraf W, Freeman BJ. Antibiotics for the eradi-cation of Propionibacterium acnes biofilms in surgical infection. J Antimic-rob Chemother 2007; 60: 1298–1301.
24. Burkhart CG, Burkhart CN. Expanding the microcomedone theory and acne therapeutics: Propionibacterium acnes biofilm produces biological glue that holds corneocytes together to form plug. J Am Acad Dermatol 2007; 57: 722–724.
25. Lomholt HB, Kilian M. Population genetic analysis of Propionibacterium acnes identifies a subpopulation and epidemic clones associated with acne. PLoS ONE 2010; 5: e12277.
26. Krakowski AC, Stendardo S, Eichenfield LF. Practical considerations in acne treatment and the clinical impact of topical combination therapy. Pediatr Dermatol 2008; 25(Suppl. 1): 1–14.
27. Kellett N, West F, Finlay AY. Conjoint analysis: a novel, rigorous tool for determining patient preferences for topical antibiotic treatment for acne. A randomised controlled trial. Br J Dermatol 2006; 154: 524–532.
28. Dreno B, Thiboutot D, Gollnick H et al. Large-scale worldwide observa-tional study of adherence with acne therapy. Int J Dermatol 2010; 49: 448–456.
29. Leyden JJ, Shalita A, Thiboutot D, Washenik K, Webster G. Topical reti-noids in inflammatory acne: a retrospective, investigator-blinded, vehicle-controlled, photographic assessment. Clin Ther 2005; 27: 216–224.
30. Thielitz A, Sidou F, Gollnick H. Control of microcomedone formation throughout a maintenance treatment with adapalene gel, 0.1%. J Eur Acad Dermatol Venereol 2007; 21: 747–753.
31. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol 2003; 49: S200–S210.
32. Schmidt N, Gans EH. Tretinoin: A review of its anti-inflammatory properties in the treatment of acne. J Clin Aesthet Dermatol 2011; 4: 22–29.
33. Liu PT, Krutzik SR, Kim J, Modlin RL. Cutting edge: all-trans retinoic acid down-regulates TLR2 expression and function. J Immunol 2005; 174: 2467–2470.
34. Grimes P, Callender V. Tazarotene cream for postinflammatory hyperpig-mentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study. Cutis 2006; 77: 45–50.
35. Cunliffe WJ, Poncet M, Loesche C, Verschoore M. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol 1998;139(Suppl. 52):48–56.
36. Del Rosso JQ, Jitpraphai W, Bhambri S, Momin S. Clindamycin phosphate 1.2%-tretinoin 0.025% gel: vehicle characteristics, stability, and tol-erability. Cutis 2008; 81: 405–408.
37. Kircik LH. Microsphere technology: hype or help? J Clin Aesthet Dermatol 2011; 4: 27–31.
38. Kligman AM, Fulton JE Jr, Plewig G. Topical vitamin A acid in acne vul-garis. Arch Dermatol 1969; 99: 469–476.
39. Martin B, Meunier C, Montels D, Watts O. Chemical stability of adapa-lene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation. Br J Dermatol 1998; 139(Suppl. 52): 8–11.
40. Dreno B. Topical antibacterial therapy for acne vulgaris. Drugs 2004; 64: 2389–2397.
41. Thielitz A, Helmdach M, Roepke EM, Gollnick H. Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents. Br J Dermatol 2001; 145: 19–27.
42. Del Rosso JQ, Schmidt NF. A review of the anti-inflammatory properties of clindamycin in the treatment of acne vulgaris. Cutis 2010; 85: 15–24.
43. Dreno B, Thiboutot D, Gollnick H et al. Antibiotic stewardship in dermatology: limiting antibiotic use in acne. Eur J Dermatol 2014; 24: 330–334.
44. Ross JI, Snelling AM, Carnegie E et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol 2003; 148: 467–478.
45. Dumont-Wallon G, Moyse D, Blouin E, Dreno B. Bacterial resistance in French acne patients. Int J Dermatol 2010; 49: 283–288.
46. Espersen F. Resistance to antibiotics used in dermatological practice. Br J Dermatol 1998; 139(Suppl. 53): 4–8.
47. Mills O Jr, Thornsberry C, Cardin CW, Smiles KA, Leyden JJ. Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle. Acta Derm Venereol 2002; 82: 260–265.
48. Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical studies. Br J Dermatol 2005; 153: 395–403.
49. Sagransky M, Yentzer BA, Feldman SR. Benzoyl peroxide: a review of its current use in the treatment of acne vulgaris. Expert Opin Pharmacother 2009; 10: 2555–2562.
50. Yentzer BA, Ade RA, Fountain JM et al. Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial. Cutis 2010; 86: 103–108.
51. Jain GK, Ahmed FJ. Adapalene pretreatment increases follicular penetra-tion of clindamycin: in vitro and in vivo studies. Indian J Dermatol Vene-reol Leprol 2007; 73: 326–329.
52. Gollnick H, Cunliffe W, Berson D et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49: S1–S37.
53. Duac. Summary of product characteristics. Stiefel (a GlaxoSmithKline Company), UK, 2011.